Hardtstock, Fraence
Heinrich, Kirstin
Wilke, Thomas
Mueller, Sabrina
Yu, Holly
Funding for this research was provided by:
Pfizer Inc (NA)
Article History
Received: 24 September 2019
Accepted: 9 March 2020
First Online: 19 March 2020
Ethics approval and consent to participate
: Because of the non-interventional, retrospective nature of this study and because our analysis involved an anonymized dataset, neither ethical review nor informed consent of the patients was required. However, the study protocol was reviewed and approved by the sickness fund (AOK PLUS), before access to the data was granted.
: Not applicable.
: This study was sponsored by Pfizer, Inc. H. Yu and K. Heinrich are employees and shareholders of Pfizer. T. Wilke has received honoraria from several pharmaceutical/consultancy companies (Novo Nordisk, AbbVie, Merck, GSK, BMS, LEO Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Pharmerit). S. Mueller and F. Hardtstock are employees of Ingress-Health who were paid consultants to Pfizer in connection with the development of this manuscript. The authors declare that they have no competing interests.